Risk Classification of Bladder Cancer by Gene Expression and Molecular Subtype
Ana Blanca(Instituto Maimónides de Investigación Biomédica de Córdoba), Liang Cheng(Brown University), Rodolfo Montironi(Marche Polytechnic University), Alessia Cimadamore(University of Udine), Andreia Bilé-Silva(University College Hospital), Kevin Lopez-Porcheron(University of Córdoba), Enrique Gómez‐Gómez(Instituto Maimónides de Investigación Biomédica de Córdoba), Antonio López-Beltrán(University of Córdoba), Rajan Gogna(Virginia Commonwealth University)
Cited by 18
Related Papers
Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine
|Modern Pathology|2017|404
Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer
|Cancers|2021|289